Tech Company Financing Transactions
Celator Pharmaceuticals Funding Round
Celator Pharmaceuticals, based in Princeton, raised $22.5 million from BDC Venture Capital, Domain Associates and Growthworks Capital.
Transaction Overview
Company Name
Announced On
7/29/2008
Transaction Type
Venture Equity
Amount
$22,500,000
Round
Series C
Investors
Proceeds Purpose
The proceeds will be used to fund Phase 2 studies of CPX-351 (a liposomal formulation of cytarabine:daunorubicin) in patients with acute myeloid leukemia.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
200 Princeton South Corporate Centre 180
Princeton, NJ 08628
USA
Princeton, NJ 08628
USA
Phone
Website
Email Address
Overview
Celator biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes in cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Jackson
Chief Financial Officer
Fred Powell
Chief Medical Officer
Arthur Louie
President
Lawrence Mayer
VP - Regulatory Affairs
Lisa DeLuca
Browse more venture capital transactions:
Prev: 7/29/2008: Heatwave Interactive venture capital transaction
Next: 7/29/2008: Alphion venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs